logo-loader
viewe-Therapeutics PLC

e-Therapeutics plc - Notice of AGM and Annual Report

RNS Number : 2735I
e-Therapeutics plc
31 March 2020
 

e-therapeutics plc

 

Notice of Annual General Meeting and Annual Report

 

31 March 2020:  e-therapeutics plc (AIM: ETX, "e-therapeutics" or the "Company"), the drug discovery company, announces that its Annual Report and Financial Statements for the year ended 31 January 2020, which includes the notice convening the Company's 2020 Annual General Meeting ("2020 AGM"), have been posted to shareholders today and can now be downloaded from the Company's website at https://www.etherapeutics.co.uk/investors/reports-results/ 

 

The 2020 AGM will take place at 11:00 am on 2 June 2020 at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH.

 

On 26 March 2020, the Government's Stay at Home Measures were passed into law in England and Wales, with immediate effect. These measures prohibit public gatherings of more than two people, except where the gathering is "essential for work purposes". Current advice is that attendance at a general meeting by a shareholder, (other than one specifically required to form the quorum for that meeting), does not meet that criteria.

 

Shareholders who wish to register their votes on the resolutions to be put to the AGM without attending in person should do so by completing and signing the proxy form that accompanied the 2020 AGM Notice (or appoint a proxy electronically if their shares are held in CREST) in accordance with the instructions printed on the proxy form. Please return your forms as soon as possible and in any event prior to 11:00 am on 29 May 2020 or not less than 48 hours before the time of the meeting or any adjourned meeting. Further information can be found in the notice of the AGM on pages 64 to 68 of the Annual Report.

 

If you do not have a proxy form and believe that you should have one, or if you have any additional queries on voting, please contact our registrar at Neville Registrars Limited, Neville House, Steelpark Road, Halesowen B62 8HD.

 

 

-Ends-

For more information, please contact:

 

e-therapeutics plc

Ali Mortazavi, Executive Chairman

 

Tel: +44 (0)1993 883 125

www.etherapeutics.co.uk 

 

Numis Securities Limited

Freddie Barnfield/Duncan Monteith (Nominated Adviser)

James Black (Corporate Broking)

 

Tel: +44 (0) 207 260 1000

www.numis.com

 

FTI Consulting

Simon Conway

Tel: +44 (0) 203 727 1000

Email: [email protected]

 

About e-therapeutics

 

e-therapeutics is an Oxford, UK-based company with a unique and powerful computer-based approach to drug discovery, founded on our industry-leading expertise in network biology.

 

We have created two proprietary, unique and productive technologies. The first is Network-driven Drug Discovery ("NDD"), which is based on cutting-edge network science, statistics, machine learning and artificial intelligence. NDD allows the more efficient discovery of new and better drugs and has been validated in multiple and diverse areas of biology.

 

The second is Genome Associated Interaction Networks ("GAINs"). GAINs is a revolutionary and entirely novel approach to functional genomics, based on the same validated network biology and analytics expertise that underpins our NDD technologies. GAINs analyses human genetic data to provide a deep and valuable understanding of the mechanisms that cause disease. GAINs has the potential to uncover unrecognised disease processes and pathways and can enable the discovery of novel drugs, diagnostics and biomarkers in a way not previously possible from population genomics data, such as genome-wide association studies ("GWAS").

 

 

We have deployed our highly productive drug discovery platform technologies to develop our own IP-protected, pre-clinical drug discovery programmes that are available to partners seeking to acquire or in-license novel and differentiated assets.

 

We have partnerships with Novo Nordisk in Type-2 diabetes and a US-based, top 5 pharmaceutical company in neurodegeneration. We are working on different types of collaborative partnerships with biotech, pharma and other technology companies to create sustainable mutual value.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NOAEALDFDELEEFA

Quick facts: e-Therapeutics PLC

Price: 19.75

Market: AIM
Market Cap: £63.68 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

e-Therapeutics begins experimental testing on first set of compounds for...

e-Therapeutics PLC's (LON:ETX) chief scientific officer Alan Whitmore speaks to Proactive London's Andrew Scott after announcing they've begun experimental testing on the first set of compounds for the treatment of coronavirus (COVID-19) identified using its proprietary network-driven drug...

1 week, 2 days ago